New Avita Medical chairman Lou ­Panaccio says the company, as well as its biotechnology sector peers, needs to better explain how and when it will deliver returns, to maintain ­support from investors with short investment horizons.

In a wide-ranging interview, which also touched on the controversial ­proposed GP co-payments, Mr Panaccio said most Australian investors see biotechnology as a speculative investment. “They’re hoping to put money in and then get out in a reasonably quick period of time," he said.